Navigation Links
Sinobiopharma Announces 350% Increase in Production of Its Flagship Drug in the First Quarter of 2009 Over the Same Period in 2008
Date:5/14/2009

NANTONG CITY, China, May 14 /PRNewswire-FirstCall/ -- Sinobiopharma, Inc. (OTC Bulletin Board: SNBP) ("Sinobiopharma" or, the "Company") is pleased to announce that production of its flagship drug, Cisatracurium Besylate, increased by 350% in the first quarter of 2009 compared to production in the first quarter of 2008.

In response to a sharp rise in orders, Sinobiopharma increased the total output of the skeletal muscle relaxant to 214,900 units in the first quarter of 2009, compared to 47,700 units for the same period in 2008.

"We were able to achieve the dramatic rise in production despite the global economic crisis and challenges within the Chinese pharmaceutical industry," said Lequn Huang, Company President and CEO. "We anticipate that demand for our flagship product, and for our newly launched anti-hypertensive, Perindopril, will continue to grow. We also expect that this growth, and planned acquisitions in 2009, will drive a higher level of performance for Company this year."

Sinobiopharma distributes Cisatracurium Besylate in 30 provinces and key major cities throughout China through sales partners and other sales networks.

About Sinobiopharma

Sinobiopharma Inc. is a fully integrated and highly innovative biotechnology company engaged in the research and development, manufacture and marketing of biopharmaceutical products in China, the world's fastest growing pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in China, the Company's current therapeutic focus is on anesthesia-assisted agents and cardiovascular drugs.

FORWARD LOOKING STATEMENTS

This news release may include "forward-looking statements" regarding Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such forward looking statements are within the meaning of Section 27A of the Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, and are intended to be covered by the safe harbor created by such sections. Where Sinobiopharma, Inc. expresses or implies an expectation or belief as to future events or results, such expectation or belief is believed to have a reasonable basis. However, forward-looking statements are subject to risks, uncertainties and other factors, which could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Sinobiopharma, Inc. does not undertake any obligation to update any forward-looking statement, except as required under applicable law.


'/>"/>
SOURCE Sinobiopharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Sinobiopharma, Inc. Signs Sales Contract for Flagship Project
2. Sinobiopharma Reports Highlights of Third Quarter Results for Its Operating Subsidiary, Dong Ying China
3. China Sky One Medical, Inc. Announces Record First Quarter 2009 Results
4. Connectyx CEO Announces Support of the Obama Plan to Invest in Health Information Technology
5. Birner Dental Management Services, Inc. Announces Net Income up 31% for the Quarter
6. Duane Reade Announces Premier-Level Sponsorship of AIDS Walk New York
7. Concentric Medical Announces Enrollment Milestone for Merci Registry
8. Natural Alternatives International, Inc. Announces Fiscal 2009 Q3 Results
9. eDiets.com(R) Announces Q1 2009 Results
10. Misonix Announces Attendance at 22nd Annual Symposium on Advanced Wound Care
11. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Texas (PRWEB) , ... June 24, 2016 , ... ... International Conference and Scientific Sessions in Dallas that it will receive two significant ... of the grants came as PHA marked its 25th anniversary by recognizing patients, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... Topical BioMedics, Inc, makers of Topricin and MyPainAway Pain ... for a minimum wage raise to $12 an hour by 2020 and then adjusting it ... the lost value of the minimum wage, assure the wage floor does not erode again, ...
(Date:6/24/2016)... ... June 24, 2016 , ... EB Medicine presented its first-ever ... Medicine conference in Ponte Vedra Beach, FL. The awards honor the outstanding work ... Practice and Pediatric Emergency Medicine Practice. , “With this award, we recognize ...
(Date:6/24/2016)... ... June 24, 2016 , ... ... Grove Investment Group (TGIG), has initiated cultivation and processing operations at its production ... and Pahrump, Nevada. , Puradigm is the manufacturer of a complete system of ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 Any dentist who has ... of the current process. Many of them do not even ... technical difficulties and high laboratory costs involved. And those who ... it at such a high cost that the majority of ... Dr. Parsa Zadeh , founder of Dental Evolutions ...
(Date:6/23/2016)... 23, 2016  In a startling report released today, National ... by lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... of how states are tackling the worst drug crisis in recorded ... – Kentucky , New Mexico ... . Of the 28 failing states, three – Michigan ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Analysis 2016 - Forecast to 2022" report to their ... contains up to date financial data derived from varied research ... trends with potential impact on the market during the next ... which comprises of sub markets, regional and country level analysis. ...
Breaking Medicine Technology: